Clinical Trials
5 trialsNCT02601313 2026-03-18
ZUMA-2
Gilead Sciences
Phase 2 Completed
NCT03105336 2025-12-23
ZUMA-5
Gilead Sciences
Phase 2 Completed
NCT04150913 2025-11-25
A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity
Massachusetts General Hospital
Phase 2 Completed
NCT04432506 2025-01-28
Anakinra for the Reduction of CAR-T Toxicity in Patients With Relapsed or Refractory Large B-cell Lymphoma
M.D. Anderson Cancer Center
Phase 2 Completed
NCT03761056 2024-12-04
ZUMA-12
Gilead Sciences
Phase 2 Completed